Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Neoplasm Metastasis 7Neoplasms 5Breast Diseases 5Neoplasms by Site 4Ovarian Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Anatomic Stage II Breast Cancer AJCC v8 2Advanced Breast Cancer 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Osteitis Deformans 1Neoplastic Cells, Circulating 1Mesothelioma 1Lymphoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Leukemia 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hematologic Neoplasms 1

Interventions

ribociclib 1LSZ102 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced or Metastatic ER+ Breast Cancer × ribociclib × Breast × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡